Physician profile
Fred Jean
NPI 1972605558
$6,082.30
in general payments reported to CMS, 2019-2025
17 companies · $923 in 2025
The $923 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $681 · 2020: $680 · 2021: $1,234 · 2022: $1,171 · 2023: $772 · 2024: $621 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,312 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.75 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,403.98 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $973.56 | 2021-2024 | |
| Alkermes, INC. | $847.20 | 2019-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $630.28 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $623.73 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $333.00 | 2019-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $289.24 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $247.95 | 2019-2023 | Invega Sustenna, Spravato |
| Allergan, INC. | $139.05 | 2019-2020 | |
| Lundbeck LLC | $135.18 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $111.89 | 2019 | |
| Vanda Pharmaceuticals INC. | $109.46 | 2020-2024 | Hetlioz, Fanapt |
| Indivior INC. | $103.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.72 | 2021-2022 | |
| Almatica Pharma LLC | $34.71 | 2022-2023 | Sertraline Hcl, Loreev Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $18.65 | 2021 | |
| Merck Sharp & Dohme LLC | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Jean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.